Overview

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

orforglipron